Tucatinib Clearance, Genetics, and Enzyme Inducers

Tucatinib is cleared mainly through CYP2C8 and CYP3A4. That means drug exposure may vary because of genetics, co-medications, and supplements that induce or inhibit these enzymes.

Why this matters

If tucatinib is cleared too quickly, drug exposure may fall.

If tucatinib is cleared too slowly, side effects may become more likely.

In practice, the most important questions are usually:

• whether another drug or supplement is changing enzyme activity

• whether inherited variation may be affecting clearance

• whether reduced exposure could be contributing to loss of efficacy

Genetic variation that may matter

Potentially relevant genes include:

• CYP3A4

• CYP2C8

• ABCB1

Examples often discussed include:

• CYP3A4*22 — associated with lower CYP3A4 activity in some settings

• CYP3A4*1G — sometimes associated with higher activity

• CYP2C8 variants such as *2 and *3 — may alter substrate handling

• ABCB1 polymorphisms — may affect drug transport and intracellular exposure

These findings are helpful context, but they do not yet translate into routine personalised tucatinib dosing for most patients.

Enzyme inducers that may increase tucatinib clearance

Known or plausible inducers include:

• St John's wort

• rifampicin

• carbamazepine

• phenytoin

• some antiretrovirals, such as efavirenz or nevirapine

• lower dose (not high-dose) Ivermectin

These may reduce tucatinib exposure by increasing CYP3A4 or CYP2C8 activity.

Natural-compound relevance

Natural compounds are usually discussed more often as inhibitors than as strong inducers.

One major exception is St John's wort, a classic inducer that should be treated as a high-priority interaction concern.

Evidence for mild induction from other supplements, including some omega-3 discussions, is much weaker and less clinically established.

Questions to discuss with the care team

• whether pharmacogenetic testing is available and useful

• whether any current medicines or supplements may be inducing CYP3A4 or CYP2C8

• whether the unexpected loss of efficacy could relate to altered exposure

• whether liver function, toxicity pattern, or co-medications suggest a clearance issue

Related pages

• HER2CLIMB Guide

• Natural Compounds and CYP3A4 — HER2CLIMB Considerations

• HER2CLIMB Resistance Mechanisms

References

Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance
https://www.sciencedirect.com/science/article/abs/pii/S0090955625090701

Kinetic and mechanistic investigation toward the characterization of tucatinib metabolism
https://pubmed.ncbi.nlm.nih.gov/40812076/

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386914/

The Pharmacokinetics and Safety of Tucatinib in Volunteers
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734226/

FDA multidisciplinary review for tucatinib
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213411Orig1s000MultidisciplineR.pdf

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form